CI Blend Pen
Synthetic peptide studied in animal and cell models for synergistic growth hormone optimization and clean selectivity profile
Last updated: March 1, 2026
- Compound
- CI Blend Pen
- Class
- Body Composition peptide
- Summary
- Synthetic peptide studied in animal and cell models for synergistic growth hormone optimization, clean selectivity profile, body composition & recovery support.
- Mechanism
- Multi-System Physiological Response
- Research Status
- Preclinical
- Routes Studied
- Subcutaneous injection via auto-injector pen
- Evidence Level
- Preclinical-promising · Clinically unproven
What Should You Know About CI Blend Pen?
- What is CI Blend Pen?
- CI Blend Pen is a synthetic peptide studied in animal and cell models for synergistic growth hormone optimization and clean selectivity profile.
- Is CI Blend Pen clinically proven?
- No. Human evidence remains limited and does not establish CI Blend Pen as clinically proven.
- What has CI Blend Pen been studied for?
- CI Blend Pen has been studied in preclinical models of synergistic growth hormone optimization, clean selectivity profile, body composition & recovery support. These findings have not been confirmed in large-scale human trials.
- Is CI Blend Pen approved?
- No. CI Blend Pen is not an approved drug and remains a research compound.
What Is CI Blend Pen?
The CI Blend Pen combines CJC-1295 (a growth hormone-releasing hormone analogue) and Ipamorelin (a selective growth hormone secretagogue) in a 10mg auto-injector pen format. This dual-peptide formulation targets growth hormone optimization through two complementary receptor systems on pituitary somatotroph cells, producing synergistic GH output significantly exceeding what either compound achieves independently. The pre-formulated pen delivery system provides precise dosing consistency and eliminates the multi-step reconstitution process required when using these...
Evidence Summary
CI Blend Pen has preliminary preclinical evidence only. Human clinical trial data is not available.
Evidence Breakdown
| Domain | Evidence Level |
|---|---|
| Synergistic Growth Hormone Optimization | Insufficient |
| Clean Selectivity Profile | Insufficient |
| Body Composition & Recovery Support | Insufficient |
| Precision Pen Delivery | Insufficient |
| Human clinical evidence | Limited |
| Safety data | Insufficient |
Editorial Position
CI Blend Pen is best understood as a preclinical research compound with promising biological signals but limited human validation. Many online claims exceed the strength of available human evidence, and safety data remains incomplete. Any consideration of this compound should involve careful evaluation of individual context and medical guidance.
Regulatory Status Snapshot
- Not approved as a therapeutic drug by major regulators
- Safety profile not established in large human populations
Need help interpreting this evidence for your situation?
Talk to a SpecialistA deep research review for CI Blend Pen is not yet available. This compound profile is based on published peer-reviewed references listed below.
Browse all research reviewsWhat Has CI Blend Pen Been Studied For?
Research areas where CI Blend Pen has been investigated in published studies
-
Synergistic Growth Hormone Optimization CI Blend Pen has been studied in animal models of synergistic growth hormone optimization. These findings have not been confirmed in controlled human trials.
-
Clean Selectivity Profile CI Blend Pen has been studied in animal models of clean selectivity profile. These findings have not been confirmed in controlled human trials.
-
Body Composition & Recovery Support CI Blend Pen has been studied in animal models of body composition & recovery support. These findings have not been confirmed in controlled human trials.
-
Precision Pen Delivery CI Blend Pen has been studied in animal models of precision pen delivery. These findings have not been confirmed in controlled human trials.
How Does CI Blend Pen Work?
These mechanisms have been observed in preclinical models. They are plausible but have not been linked to proven clinical outcomes in humans.
- 01 Ipamorelin GHS-R1a Receptor Activation
- 02 CJC-1295 GHRH Receptor Amplification
- 03 Synergistic GH Pulse Generation
- 04 Hepatic IGF-1 Synthesis
Not sure if CI Blend Pen is right for you?
A specialist can review the evidence, evaluate your medical context, and help you make an informed decision about CI Blend Pen.
Community Reports (Anecdotal)
Experiences shared here are self-reported and do not represent clinical evidence.
Rate CI Blend Pen
How Is CI Blend Pen Administered?
CI Blend Pen is available via Subcutaneous injection via auto-injector pen. Appropriate use and protocol should be determined by a qualified specialist.
What Are the Specifications of CI Blend Pen?
What Conditions Has CI Blend Pen Been Linked To?
Have Questions About CI Blend Pen?
Ipamorelin demonstrates a uniquely selective GH-releasing profile. Research published in the European Journal of Endocrinology confirmed that Ipamorelin produces dose-dependent growth hormone elevation without corresponding increases in cortisol, prolactin, or aldosterone.
Published studies on CI Blend Pen can be found on PubMed and other peer-reviewed databases. Our references section below lists key citations.
CI Blend Pen is available as a research compound in Thailand. Consult a qualified specialist to discuss whether it is appropriate for your needs.
Ready to discuss CI Blend Pen with a specialist?
Get evidence-based guidance tailored to your health goals and medical context.
Book a Consultation Free initial consultation. No obligation.Reviewed by the Peptide Science Thailand Editorial Team.
Last reviewed: March 1, 2026